دورية
Efficacy and Safety of Fostamatinib for Immune Thrombocytopenia in Clinical Practice in Spain: Interim Results of Fostames, Our National Fostamatinib Registry
| العنوان: | Efficacy and Safety of Fostamatinib for Immune Thrombocytopenia in Clinical Practice in Spain: Interim Results of Fostames, Our National Fostamatinib Registry |
|---|---|
| المؤلفون: | Gonzalez-Lopez, Tomas Jose, Perez Segura, Gloria, Domingo, Abel, Lopez Ansoar, Elsa, Diaz Galvez, Francisco Javier, Jimenez Barcenas, Reyes, Martinez Carballeira, Daniel, De Miguel Llorente, Dunia, Perona Blazquez, Alvaro, Aguilar-Monserrate, Gerardo, Dávila-Valls, Julio, Gonzalez Gascon, Isabel, Cuesta, Amalia, Bengochea Casado, María Luisa, Hermida Fernandez, Gerardo Julio, Alonso Alonso, Jose Maria, Pozas Mañas, Miguel Angel, Torres-Tienza, Ana, Aguilar, Carlos, Fernandez-Jimenez, Dolores, Soto, Inmaculada, Bernat, Silvia |
| المصدر: | Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p2591-2591, 1p |
| مستخلص: | Background: Fostamatinib is a splenic tyrosine kinase (SYK) inhibitor that prevents antibody-mediated platelet destruction. This drug has demonstrated to be effective and safe in immune thrombocytopenia (ITP). However, clinical trials may not accurately reflect what happens in clinical practice. Here we evaluated the efficacy and safety of eltrombopag in ITP in a real-world setting. |
| قاعدة البيانات: | Supplemental Index |
| تدمد: | 00064971 15280020 |
|---|---|
| DOI: | 10.1182/blood-2023-190511 |